Objective: Selective laser amygdalohippocampotomy (SLAH) using magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is emerging as a treatment option for drug-resistant mesial temporal lobe epilepsy (MTLE). SLAH is less invasive than open resection, but there are limited series reporting its safety and efficacy, particularly in patients without clear evidence of mesial temporal sclerosis (MTS). Methods: We report seizure outcomes and complications in our first 30 patients who underwent SLAH for drug-resistant MTLE between January 2013 and December 2016. We compare patients who required stereoelectroencephalography (SEEG) to confirm mesial temporal onset with those treated based on imaging evidence of MTS. Results: Twelve patients with SEEG-confirmed, non-MTS MTLE and 18 patients with MRI-confirmed MTS underwent SLAH. MTS patients were older (median age 50 vs 30 years) and had longer standing epilepsy (median 40.5 vs 5.5 years) than non-MTS patients. Engel class I seizure freedom was achieved in 7 of 12 non-MTS patients (58%, 95% confidence interval [CI] 30%-86%) and 10 of 18 MTS patients (56%, 95% CI 33%-79%), with no significant difference between groups (odds ratio [OR] 1.12, 95% CI 0.26-4.91, P = .88). Length of stay was 1 day for most patients (range 0-3 days). Procedural complications were rare and without long-term sequelae. Significance: We report similar rates of seizure freedom following SLAH in patients with MTS and SEEG-confirmed, non-MTS MTLE. Consistent with early literature, these rates are slightly lower than typically observed with surgical resection (60%-80%). However, SLAH is less invasive than open surgery, with
| INTRODUCTION
Mesial temporal lobe epilepsy (MTLE), in which seizures arise from the amygdalohippocampus and adjacent structures, is the most common cause of pharmacoresistant epilepsy. 1 For these patients, stereotactic laser amygdalohippocampotomy (SLAH) using magnetic resonanceguided laser interstitial therapy (MRgLITT) is emerging as an important surgical option. Reported rates of seizure freedom in published series of SLAH [2] [3] [4] [5] [6] appear to be slightly lower than with anterior temporal lobectomy, [7] [8] [9] [10] which has proven efficacy in 2 class I trials. 7, 8 However, SLAH is
less invasive than open surgery with shorter inpatient length of stay and recovery time. Patients unwilling to consider open surgery may be more amenable to a minimally invasive approach. 11, 12 SLAH also causes less damage to the lateral temporal neocortex, and preliminary reports suggest that it may have less negative impact on memory and language function. 3, 5 Some have suggested that SLAH may be the preferable first-line surgical option for MTLE, with open surgery reserved for those with persistent seizures after one or more failed ablations. 5, 11, 12 Although MRgLITT is a promising approach to the treatment of MTLE, it is still a relatively new procedure. Appropriate indications and predictors of safety and efficacy have not been well characterized in larger series. Oneyear seizure freedom rates have been reported in fewer than 50 patients, [2] [3] [4] [5] [6] 13 and it will be several years before the results of the Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) trial-an ongoing, large prospective cohort study-are available. 14 Furthermore, most reported cases have been in patients with magnetic resonance imaging (MRI) evidence of mesial temporal sclerosis (MTS). Patients with nonlesional MTLE, equivocal MRI findings, or inconsistent localization on noninvasive workup will largely be excluded from the SLATE study.
Patients with MTS are more likely to achieve seizure freedom with anterior temporal lobectomy (ATL) than those without, [15] [16] [17] [18] and are therefore a logical initial target population for SLAH. However, with invasive monitoring and the growth of robot-assisted stereoelectroencephalography (SEEG), the seizure-onset zone can often be localized to the mesial temporal lobe structures. [19] [20] [21] [22] The likelihood of achieving seizure freedom with SLAH in this challenging patient population remains largely unknown.
In the current series, we present our experience with SLAH for the treatment of MTLE. We describe preoperative clinical characteristics, seizure outcomes, length of stay, and adverse events for patients with MRI-documented MTS in comparison with patients with non-MTS, SEEGconfirmed hippocampal-onset MTLE. We then synthesize the available evidence for SLAH, with special attention to its role in the treatment of MTLE without MTS.
| METHODS

| Patient population
Consecutive patients undergoing MRgLITT for MTLE at our institution between January 2013 and December 2016
Key Points
• Selective laser amygdalohippocampotomy (SLAH) is an alternative to open resection for the treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), but there are limited series reporting its safety and efficacy
• Patients with mesial temporal sclerosis (MTS) are more likely than those without it to achieve seizure freedom after open surgery; it is unclear if this difference holds true with laser ablation or if localization with stereoelectroencephalography (SEEG) influences these outcomes
• We report similar rates of seizure freedom following SLAH in patients with MTS (56%) and those with non-MTS, SEEG-confirmed MTLE (58%)
• SLAH may be a reasonable first-line surgical option for patients with both MTS and non-MTS MTLE and requires further study in both populations were identified from a prospectively maintained clinical database. All candidates for surgery had persistent seizures after tolerating trials of at least 2 appropriately chosen antiepileptic drugs (AEDs). 23 Standard presurgical evaluation included neurologic history and examination, detailed seizure and antiepileptic medication history, neuropsychological testing, brain MRI with thin-section coronal T1 and fluid-attenuated inversion recovery (FLAIR) or T2 sequences, inpatient continuous video electroencephalography (EEG) monitoring, and 18-fluoro-deoxyglucose positron emission tomography (FDG-PET). Additional diagnostic tests, including functional MRI and intracarotid methohexital (Wada) test, were performed at the discretion of the epileptologist and surgeon based on clinical indication.
Patients were discussed in a weekly multidisciplinary case conference. Patients were determined to have MTS by a board-certified neuroradiologist together with multidisciplinary case conference review if the preoperative MRI demonstrated mesial temporal atrophy accompanied by either increased signal on T2-weighted image or loss of internal architecture in the hippocampus. Patients with MTS and a concordant workup were surgical treatment candidates. The remaining non-MTS temporal-onset epilepsy patients were confirmed to have mesial temporal hippocampal seizure onsets with SEEG. SEEG investigations were planned in multidisciplinary case conference and varied based on the findings of the noninvasive workup. Patients with MTS or SEEG-confirmed MTLE were given the choice between SLAH and open surgical resection. After a full discussion of known risks and benefits associated with each procedure, patients made the final choice of approach, and the operating surgeon obtained informed consent. The Columbia University Medical Center Institutional Review Board approved this study.
| Robot-assisted SEEG technique
All SEEG procedures were performed with the ROSA robotic assistant device (Medtech, Montpellier, France). Preoperative T1 contrast-enhanced MRI results were transferred to the ROSA Brain stereotactic planning software. Trajectories were planned based on the preimplantation hypothesis of the seizure-onset zone. All investigations in this series included temporo-limbic coverage, consisting of 6 to 9 depth electrodes targeting unilateral amygdala, hippocampal head, body, and tail, anterior cingulate, anterior insula, orbitofrontal cortex, and posterior basal temporal lobe. Additional coverage, including contralateral sampling, was planned in the interdisciplinary conference based on the noninvasive workup. Details for each patient are provided in the Results.
On the day of surgery, patients were induced under general endotracheal anesthesia, fixed in a Cosman-RobertsWells (CRW) headframe (Integra LifeSciences Corporation, Plainsboro, NJ, USA), and registered using laser-based facial recognition. The robotic arm was positioned for each trajectory and a guide sleeve fixed in its platform. A twist drill hole was made using a 2.4-mm diameter drill (Stryker Medical, Kalamazoo, MI, USA). The dura was cauterized and opened with insulated perforators and monopolar cautery, and an anchor bolt (PMT Corporation, Chanhassen, MN, USA) was secured in the drill hole. A 0.8-mm diameter blunt, rigid stylet was then passed through the parenchyma to create a track, and finally the electrode (PMT Corp, 0.8-mm diameter, 5-mm contact space) was inserted to its premeasured depth and secured. The procedure was repeated for each trajectory, and electrode positions were confirmed postoperatively with a volumetric computed tomography scan.
Patients underwent monitoring and electrographic recording in the epilepsy monitoring unit (EMU). Antiepileptic medications were weaned and seizure provocation techniques employed as needed. Ictal were and interictal findings were discussed at case conference, and patients in whom the hippocampus was implicated in seizure onset were determined to be treatment candidates.
| Laser ablation procedural technique
All ablations were performed using the Visualase MRIguided laser ablation system (Medtronic Inc, Minneapolis, MN, USA) as depicted in Figure 1 . Stereotactic placement of the laser fiber assembly was performed using the Brainlab iPlan stereotactic planning software (BrainLAB AG, Munich, Germany) and a CRW Precision Arc System stereotactic frame (Integra LifeSciences Corporation) or the ROSA surgical robot. A trajectory was planned along the long axis of the amygdalohippocampal complex from an occipital entry point that avoided prominent surface and sulcal vasculature. 24, 25 We attempted to avoid the ventricle, but occasionally would have to transgress the occipital horn.
With the patient under general endotracheal anesthesia, a small stab incision was made at the entry site, a 3.2-mm burr hole was drilled along the planned trajectory, and a skull-mounted titanium anchor bolt (PMT Model 2103-19-25 mm) was inserted. After coagulating the dura and passing a stylet, the laser cooling catheter and fiber were inserted to the stereotactic target distance and secured with the anchor bolt cap. The patient was then transferred to a 3.0 Tesla MRI scanner (General Electric, North Bergen, NJ, USA). Intersecting planning T1 MRI slices were obtained to allow the ablation to be monitored in 2 orthogonal planes (typically sagittal and axial oblique). Low and high safety points were set at 45°C and 90°C, respectively, as described elsewhere. 11, 26 During the ablation, fast spoiled gradient-recalled echo images were obtained at 4-s intervals per acquisition and imported continuously to the Visualase workstation for derivation of thermal phase maps and cumulative irreversible damage zone. 11, 27 After the desired ablation was achieved with the laser in its initial position, the inner fiber was withdrawn from the outer catheter in 8-10 mm increments to complete a total of 3-5 serial ablations along the trajectory of the fiber. The anterior medial wall of the posterior temporal lateral ventricle was used as a posterior F I G U R E 1 Mesial temporal laser ablation procedure. A, A trajectory is planned along the long axis of the amygdalohippocampal complex from an occipital entry point that avoids prominent surface and sulcal vasculature. B, The laser fiber assembly is inserted to the stereotactic target in the operating room. C, The patient is transferred to MRI where intersecting planning T1 slices are obtained to allow the ablation to be monitored in 2 orthogonal planes. D, During the ablation, fast spoiled gradient-recalled echo images are obtained at 4-s intervals per acquisition and imported continuously to the Visualase workstation for derivation of thermal phase maps. Low safety points (numbered) protect adjacent structures and high safety points prevent excess heat at the catheter tip. The "irreversible damage zone" is calculated based on the cumulative effects of the time-temperature history of each image voxel and depicted as an overlay on anatomic images. After the desired ablation is achieved with the laser in its initial position, the inner fiber is withdrawn from the outer catheter in 8-10 mm increments to complete a total of 3-5 serial ablations along the trajectory of the fiber. (E) Postoperative diffusion-weighted and contrast-enhanced T1 images are obtained to confirm the anticipated ablations.
limit of ablation to avoid lesioning the optic radiations on the lateral aspect of the ventricle. This posterior limit would typically correspond with the superior and medial turn of the hippocampus at the level of the quadrigeminal plate. Postoperative diffusion-weighted and/or contrastenhanced T1 images were obtained to confirm the anticipated ablations. The catheter/fiber assembly and anchor bolt were removed in the MRI scanner holding area, the incision irrigated and closed with a single suture, and the patient was extubated and transferred to the recovery room.
In the immediate postoperative period, patients were continued on their current antiepileptic regimen and given a 2-week dexamethasone taper.
| Data collection and outcomes assessment
Patient data were obtained from physician notes, original diagnostic tests, and reports in the medical record. The patient's primary neurologist assessed clinical seizure outcomes at office visits, and 2 independent board certified epileptologists (L.M.B., C.A.S.) confirmed the modified Engel class. 28 Perioperative seizures within 14 days were not counted toward seizure outcome based on rationale given in prior series that perioperative seizures may be due to edema and irritation from surgery and not reflect the epileptogenic potential of the remaining tissue after this temporary state has resolved. 5 One patient underwent ATL for persistent seizures after SLAH, and her outcome is reported at last follow-up prior to ATL. All statistics were performed in SAS version 9.4 (SAS Institute, Cary, NC, USA). Adjusted Wald method was used to calculate binomial 95% confidence intervals (CIs) for seizure freedom rates. Fisher's exact test and Wilcoxon rank-sum test were used to compare categorical and numerical outcomes, respectively.
| RESULTS
| Patient characteristics
A total of 30 patients, including 12 non-MTS patients with SEEG-confirmed MTLE and 18 with MRI-confirmed MTS underwent SLAH between July 2013 and December 2016 at our institution (Table 1 ). There were 18 female and 12 male patients. Nineteen patients underwent right-sided ablations and 11 had left-sided ablations. The median age at the time of surgery was 43.5 years (range 19-69 years). The median age at epilepsy onset was 13 years (range from 3 weeks to 51 years), and the median epilepsy duration at the time of surgery was 19.5 years (range 2-66 years). MTS patients were older than SEEG patients at the time of surgery (median age 50 vs 30 years, P = .038) and had longer standing epilepsy (median 40.5 vs 5.5 years, P = .001).
| Seizure localization
Among the 12 SEEG patients (Table 2a) , 5 had no abnormality on MRI and 3 had completely normal-appearing mesial temporal structures with adjacent or remote MRI abnormalities (ie, choroidal fissure cyst, possible focal cortical dysplasia [FCD] , periventricular heterotopias). Four patients had subtle mesial temporal volume loss without sufficient T2 signal or loss of internal hippocampus architecture to diagnose MTS. Two of these patients also had associated findings (ie, temporal cavernous malformations, a small hippocampal cyst).
Five patients had no suspected seizure foci beyond the mesial temporal lobe and underwent standard unilateral temporolimbic investigations to confirm mesial temporal onset. Seven patients had additional imaging findings or discordant noninvasive EEG results (indicated by bold font in Table 2a ) prompting additional SEEG coverage, including 4 bilateral investigations. All 12 patients who underwent SLAH had seizure onset localized to the mesial temporal lobe. Two patients (15 and 21) also had early involvement of ipsilateral, adjacent temporooccipital heterotopias that were ablated through second trajectories during the same procedure. There was variability among the SEEG findings of the 12 patients in terms of potential involvement of temporal neocortex and extratemporal circuit structures in seizure onset. This variability was taken into consideration in the informed-consent process; however, all patients elected to pursue SLAH with the option of additional diagnostic or treatment surgery in the future if seizures persisted. Among the 18 patients with MTS (Table 2b) , noninvasive ictal EEG localized seizures to the side of MTS and ablation in all patients (although 2 patients had possible contralateral onset) and interictal EEG supported that localization in 17 patients (although 7 also had contralateral slowing or spiking). There was asymmetric hypometabolism favoring the target mesial temporal lobe in 14 of the 15 patients who had an FDG-PET.
| Efficacy
Of the 30 patients who underwent SLAH, 17 (57%, 95% CI 39%-73%) remained Engel class I seizure-free at last follow-up (median follow-up 17 months, range 12-36 months) (Table 3) . Seizure freedom was achieved in 7 of 12 SEEG patients (58%, 95% CI 30%-86%) and 10 of 18 MTS patients (56%, 95% CI 33%-79%), with no significant difference between groups (odds ratio [OR] 1.12, 95% CI 0.26-4.91, P = .88). All patients had at least 12 months follow-up, and median follow-up was similar between groups.
In the full cohort, 1 patient (3%) was Engel class II, 8 (27%) were class III, and 4 (13%) were class IV. One MTS patient (no. 1) achieved worthwhile seizure reduction (Engel class 3A) at 36 months prior to undergoing open ATL, and this is reported as her last follow-up outcome.
Six of the 17 Engel class I patients (2 SEEG patients and 4 MTS patients) also underwent and tolerated decreases in their dose or number of antiepileptic medications at last follow-up.
| Recovery and adverse events
Most patients (25 of 30; 83%) spent 1 night in the hospital and were discharged home on the first postoperative day. Four MTS patients stayed longer (3 for 2 days and 1 for 3 days) for pain management or EMU monitoring for postoperative seizure control before going home. One SEEG patient went home the same day as surgery by request.
Three patients had procedural complications without long-term sequelae. One SEEG patient (no. 12) experienced a transient superior quadrantanopia that resolved after 3 months. One MTS patient (no. 5) required a second surgery through a new trajectory to complete the desired ablation. The trajectory that was planned into the hippocampus slightly deflected and resulted in the laser fiber running within the temporal horn of the ventricle and then exiting anteriorly into the amygdala. The first ablation lesioned primarily the amygdala, as the intraventricular portion of the fiber above the hippocampus was not ablated for safety reasons. A subsequent second trajectory was necessary to ablate the hippocampal body and tail. Finally, another MTS patient presented 1 week after surgery with progressive headache and was found to have an approximately 5 cc intracerebral hemorrhage (ICH) at the right mesial temporal ablation site with adjacent intraventricular hemorrhage (IVH) on head computed tomography (CT). He was admitted to the intensive care unit and observed for 2 days, after which the headache improved, and he was discharged without neurologic deficit. Of note, this patient also had additional risk factors including a history of postcardiac transplantation ischemic stroke and a subdural hematoma, and active lymphoproliferative disorder at the time of ablation. Nine patients (3 SEEG patients and 6 MTS patients) had postoperative seizures, 4 within the first 24 hours of surgery and an additional 5 within the first 14 days. All were similar in semiology to the patient's preoperative seizures, self-limited, and resolved with continuation of the patient's home AED regimen. Postoperative seizures did not predict long-term seizure outcome: 5 patients ultimately obtained seizure freedom and 4 did not. 
| DISCUSSION
We report a consecutive series of 30 patients, 12 without MTS who had SEEG-confirmed MTLE and 18 with MRIconfirmed MTS, who underwent MRgLITT of the mesial temporal lobe. Seizure freedom was achieved in 57% of patients overall and did not differ significantly between groups: 7 of 12 (58%) non-MTS SEEG patients and 10 of 18 (56%) MTS patients were seizure-free at last follow-up. Our cohort is among the largest mesial temporal laser ablation series to date, 5, 6 and our overall seizure freedom and complication rates support the published experience. Moreover, our findings offer early evidence that by confirming mesial temporal onset with SEEG, patients without MTS can achieve rates of seizure freedom similar to those with MRI-diagnosed MTS. The overall 57% rate of seizure freedom in our cohort is consistent with other published series, 2, 3, 5, 6 which reported rates between 54% and 65%. Seizure freedom rates with SLAH appear to be slightly lower than with ATL, the gold standard surgical treatment for MTLE, which has been demonstrated in larger series with longer follow-up to yield seizure freedom rates ranging from 60% to 80% in appropriately chosen patients. [7] [8] [9] [10] In 2 recent meta-analyses, 9, 10 selective amygdalohippocampectomy (SAH), which spares the lateral temporal neocortex, had a slightly lower pooled seizure freedom rate than ATL (approximately 67% vs 73% in both studies), but both appear more likely to achieve seizure freedom than SLAH. Most patients in published series of SLAH had MTS, and limited data are available specifically on the response rate in other MTLE patients. Use of intracranial depth electrodes to confirm seizure onset in this population is variable. The largest and most favorable experience is reported in Jermakowicz et al. 6 In their series of 23 SLAH patients, 5 of 8 (63%) without MTS were seizurefree with a minimum 1-year follow-up. This rate was slightly lower than the 73% rate of seizure freedom achieved in the MTS patients, but the difference did not meet statistical significance. Some of these patients may have had intracranial recording, but further details were not provided. A handful of cases were reported in earlier series with variable detail and results. In the series of 13 patients of Willie et al, only 1 of 4 patients without MTS was free of disabling seizures, whereas 6 of 9 patients with MTS achieved seizure freedom (median follow-up 14 months, range . Notably the non-MTS responder was the only patient to have seizure onset confirmed by depth electrodes. A larger series from the same institution and reported in Drane et al. 3 included 9 patients without MTS, but the study was focused on neuropsychological outcomes, and seizure freedom for this cohort was not published. In a more recent review article, 12 the authors note that in their extended series, 3 of 4 patients without MTS and seizure onset localized to the hippocampus with depth electrodes were seizure-free at 12 months. They also report that seizure freedom in MTS patients may approach 70%. with temporal plus epilepsy, characterized by a primary temporal lobe epileptogenic zone extending to adjacent regions on SEEG, were found to be at increased risk of persistent seizures after standard ATL, compared to those with confirmed seizure onsets within the resected tissue. Suresh et al. 20 used SEEG to localize seizure onset in patients with nonlesional temporal lobe epilepsy and guide the choice of ATL, cortical resection, or multiple hippocampal transection. Seizure freedom was achieved in 13 of 18 (76%) patients, and the remainder had a reduction in seizure frequency. Similarly, Kubota et al. 31 used SEEG to tailor temporal lobe epilepsy surgery in a small series. Seven patients found to have both medial and lateral onset received ATL, whereas 4 patients with medial onset only underwent a more limited SAH. Ten of the 11 (91%) patients were seizure-free after a minimum of 2 years of follow-up. In our series, seizure freedom was achieved in 3 of 4 patients with extrahippocampal imaging findings, including 1 of the 2 patients who had concurrent ablations of periventricular heterotopias based on SEEG evidence of multifocal early onset from both the hippocampus and that area. Including these patients potentially confounds our conclusions about mesial temporal laser ablation, but they are demonstrative of the potential utility of SEEG for customizing ablations in this complex cohort. Other than these 2 cases, there was no attempt to modify the ablation target based on SEEG findings or the lack of MRI evidence of MTS, and mean ablation volumes was not significantly different between groups. We use PET hypometabolism as one of several factors to guide SEEG investigations. Notably, 11 of 12 non-MTS patients had PET hypometabolism in the mesial temporal lobe that was ultimately ablated, although this was considered mild in 2 patients and 1 patient also had mild hypometabolism in the contralateral mesial temporal lobe. Patients with mesial temporal PET hypometabolism but discordant SEEG findings were not candidates for mesial temporal ablations and were not included in this study. However, the high rate of PET positivity in those who ultimately had SEEG-confirmed mesial temporal onset warrants further investigation of the ability of PET to predict SEEG localization and ultimately seizure freedom in larger, more heterogeneous series (ie, including PET-negative patients).
There is mixed evidence that the volume and completeness of the mesial ablation contributes to the likelihood of seizure freedom in cohorts with predominantly MTS. 5, 6 It is plausible that patients without focal hippocampal sclerosis are more likely to see an added benefit from larger ablations or open surgery if these patients are presumed to have more diffuse epileptogenic zones. However, prevalence studies suggest that many cases of MR-negative MTLE actually have MTS when it is defined by histopathology. 1 Truly nonlesional cases are relatively rare (16% by histopathology compared to 44% by MRI), and the higher rate of seizure freedom seen after surgery in MTS patients narrows when MTS is defined by histopathology rather than MRI. Our findings suggest that when seizure onset can be localized to the hippocampus in patients with a negative or equivocal MRI, a focused ablation can achieve seizure freedom at a reasonable rate. Our short length of stay and low rate of procedural complications is consistent with other series and provides further support for considering SLAH as a first-line treatment option with the availability of further ablations or open resection if seizures persist. As in previous series, our patients typically went home the day after the procedure and were back to usual activities in less than a week. By contrast, patients undergoing open resection have reported median hospital stays ranging from 3 to 5 days and, typically, a 4-6 week recovery time. 5, 32 Serious complications such as hemorrhage, visual field deficit, and cranial nerve deficits appear to be lower than with open procedures and may be largely avoidable with additional experience and improved technique. 12 Wound infections occur at a rate of approximately 1.4%-4.7% after craniotomy for temporal lobe epilepsy, 32 whereas none have been reported with SLAH. Our findings suggest these benefits may apply to patients with MTLE without MTS as well. Neurocognitive outcomes, while beyond the scope of this study, warrant further consideration when considering ablation in nonlesional MTLE. Memory is generally better preserved in patients without MTS, and patients with nonlesional MTLE and intact memory are likely at greater risk of a new deficit from ablation. However, compared to open surgery, laser ablation can better spare the lateral neocortex and there is early evidence that at least some components of verbal memory may be relatively preserved. 3, 5, 6 To identify predictors of cognitive decline, larger studies will need to account for not only the presence or absence of MTS, but also preoperative neurocognitive function, dominance vs nondominance, and the extent of the ablation in the lateral neocortex. Results will also need to be compared with other minimally invasive approaches and nondestructive, neuromodulatory treatment options. Further limitations of our study include the small sample size, differential follow-up, and longer duration of epilepsy in the MTS group. Given the sample size and the 56% seizure freedom rate in the MTS group, the study was powered to detect a seizure freedom rate of 36% or lower in the non-MTS group. The gap is likely greater than the minimum meaningful clinical difference, and our study therefore provides insufficient evidence to claim that there is no different between groups. Rather we provide early evidence that SLAH achieves a sufficient rate of seizure freedom in SEEG-confirmed MTLE to maintain it as a treatment option in these patients with careful observation of results. Larger studies will be needed to determine predictors of seizure freedom and longer follow-up will also be needed to confirm results. Finally, the MTS patients were older and had longer duration epilepsy than the other MTLE patients, but this disparity likely reflects the epidemiology of the diseases, and there appears to be no difference in response to surgical treatment between those with childhood-and adult-onset seizures in MTS. 33 
| CONCLUSIONS
We report similar rates of seizure freedom following SLAH in patients with MTS (56%) in comparison to patients without MTS but with SEEG-confirmed MTLE (58%). Consistent with the early literature, these rates are slightly lower than typically observed with surgical resection (60%-80%). However, SLAH is less invasive than open surgery, with shorter hospital stays and recovery, and severe procedural complications are rare. The study is limited by a small sample size and variable follow-up. In addition, MTS patients were notably older with longer-standing epilepsy than SEEG patients. However, our findings offer early evidence that by confirming mesial temporal onset with SEEG, patients without MTS can achieve rates of seizure freedom following laser ablation similar to those with MRI-diagnosed MTS. SLAH may be a reasonable first-line surgical option for patients with both MTS and non-MTS MTLE and requires further study in both populations.
